0001127602-23-009392.txt : 20230308 0001127602-23-009392.hdr.sgml : 20230308 20230308063455 ACCESSION NUMBER: 0001127602-23-009392 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230306 FILED AS OF DATE: 20230308 DATE AS OF CHANGE: 20230308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vitoc Vlad CENTRAL INDEX KEY: 0001913257 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41455 FILM NUMBER: 23714822 MAIL ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAIA Biotechnology, Inc. CENTRAL INDEX KEY: 0001878313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 312-416-8592 MAIL ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-03-06 0001878313 MAIA Biotechnology, Inc. MAIA 0001913257 Vitoc Vlad 444 WEST LAKE STREET, CHICAGO IL 60606 1 1 1 Chief Executive Officer Common Stock 210000 I See Footnote Common Stock 2023-03-06 4 P 0 544 4.24 A 798101 D Common Stock 2023-03-07 4 P 0 1439 4.24 A 799540 D These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Vitoc that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.23 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.21 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. /s/ Vlad Vitoc 2023-03-08